HILTON LONDON OLYMPIA LONDON, UK

OCTOBER 22-24 2018

Day
Hour
Minute
Second

Precision CRISPR Congress supports pharma and biotech community in realising the drug discovery & gene therapy applications of optimised CRISPR systems

WHEN:

22-24 OCTOBER 2018

WHERE:

LONDON, UK

SOCIAL:

#PrecisionCRISPR  

 

Precision CRISPR: Drug Development & Gene Therapy Congress returns for the 3rd time, just in time to face the building excitement in getting CRISPR gene therapy into the clinic. Join us to take part in the conversations around the future of CRISPR gene editing in Europe and the rest of the world.

Through a dynamic program of focused sessions, interactive discussions and networking opportunities, you will leave this meeting with a deep understanding of:

  • the challenges in delivery & reducing off-target effects in ex vivo & in vivo gene therapies
  • how the likes of GSK, Novartis, AstraZeneca and more, work towards improving the efficacy of functional screening and drug discovery
  • the most recent gene editing techniques and Cas variants poised to make precise gene editing all that more precise

EXPERT SPEAKERS HIGHLIGHTS

Jacob Corn

Jacob Corn
Professor
ETH Zurich

Lin Wu photo

Lin Wu
Director
Genome Modification
Facility

Barry Rosen

Barry Rosen
VP & & Senior Principal
Scientist
AstraZeneca

Eric Paul Bennett

Eric Paul Bennet
Associate professor
University of
Copenhagen

CASE STUDIES YOU CAN'T AFFORD TO MISS

"Gene Repair in Human Hematopoietic Stem Cells"

An exciting session from Jacob Corn, where he will share his findings on systematic approach for generating knock-ins in stem cells; Identifying and improving precision of HDR events; And the Use of live imaging and gene editing to explore cell states.

"Detection of in vitro and ex vivo Cellular indel Profiles and Dynamics Induced By Different CRISPR/Cas9 Delivery Formats"

Learn from Eric Paul Bennet, about methodologies for absolute identification of cellular Cas9 induced indel events and ask about the In Vitro and Ex Vivo Indel formation, dynamics and profiles induced by various CRISPR/
Cas9 delivery formats

"Single-Cell CRISPR Sequencing in Drug Discovery"

Talk with Quin Wills, about how Genetic epidemiology and CRISPR screens still struggle to comment about drug target modifiers. Find out how he is dissecting out the cross-talk between metabolic pathways to understand target
interactions, with liver organoid models.

Become part of a dedicated community in Europe, striving to realise the drug discovery & gene therapy applications of optimised CRISPR systems.

MEET OUR PARTNERS

PROGRAM PARTNER

SPOTLIGHT PARTNER

SPOTLIGHT PARTNER

EXHIBITOR

EXHIBITOR

MEDIA PARTNER

MEDIA PARTNER

MEDIA PARTNER

PART OF THE PRECISION CRISPR SERIES